<?xml version="1.0" encoding="UTF-8"?>
<response>

<lst name="responseHeader">
  <int name="status">0</int>
  <int name="QTime">18</int>
  <lst name="params">
    <str name="echoParams">explicit</str>
    <str name="indent">true</str>
    <str name="file">data-lines/./reut2-005.sgm-710.txt</str>
    <str name="usePOS">true</str>
    <str name="sentences">3</str>
    <str name="wt">xml</str>
    <str name="formula">augNorm_inverse</str>
  </lst>
</lst>
<lst name="analysis">
  <lst name="summary">
    <lst name="stats">
      <lst name="sentences">
        <int name="count">16</int>
      </lst>
      <lst name="terms">
        <int name="count">84</int>
      </lst>
      <lst name="stems">
        <int name="count">50</int>
      </lst>
    </lst>
    <lst name="terms">
      <lst name="term">
        <str name="text">three</str>
        <double name="strength">1.0</double>
      </lst>
      <lst name="term">
        <str name="text">allergan</str>
        <double name="strength">0.9999999999999997</double>
      </lst>
      <lst name="term">
        <str name="text">nondilutive</str>
        <double name="strength">0.9840539975201802</double>
      </lst>
      <lst name="term">
        <str name="text">acquisitions</str>
        <double name="strength">0.9840539975201802</double>
      </lst>
      <lst name="term">
        <str name="text">possibility</str>
        <double name="strength">0.9840539975201802</double>
      </lst>
    </lst>
    <lst name="sentences">
      <lst name="sentence">
        <str name="text">It said its Smith Kline and French Laboratories pharmaceuticals unit, with 1986 sales of 1.9 billion dlrs, will file for Food and Drug Administration marketing approval for a number of cardiovascular agents, including tissue plasminogen activator, over the next two years.</str>
        <int name="index">8</int>
        <int name="start">1</int>
        <int name="end">273</int>
        <double name="strength">1.0</double>
        <int name="terms">17</int>
      </lst>
      <lst name="sentence">
        <str name="text">SmithKline Beckman Corp said it is pursuing a three-point stragey that will achieve a 10 pct annual increase in operating earnings throughout the remainder of the decade.</str>
        <int name="index">0</int>
        <int name="start">0</int>
        <int name="end">170</int>
        <double name="strength">0.864226962000261</double>
        <int name="terms">12</int>
      </lst>
      <lst name="sentence">
        <str name="text">To bolster its position in the antiulcer market, in which Tagamet has met stiff competition, SmithKline said its strategy to develop an over-the-counter version of Tagamet is bolstered by two joint ventures, one with &lt;Wellcome PLC&gt;, and one pending venture in Japan.</str>
        <int name="index">4</int>
        <int name="start">1</int>
        <int name="end">267</int>
        <double name="strength">0.8070650574088584</double>
        <int name="terms">15</int>
      </lst>
    </lst>
    <lst name="highlighted">
      <lst name="sentence">
        <str name="text">It said its &lt;em&gt;Smith Kline&lt;/em&gt; and &lt;em&gt;French Laboratories pharmaceuticals&lt;/em&gt; unit, with 1986 &lt;em&gt;sales&lt;/em&gt; of 1.9 &lt;em&gt;billion&lt;/em&gt; dlrs, will file for Food and Drug &lt;em&gt;Administration marketing approval&lt;/em&gt; for a &lt;em&gt;number&lt;/em&gt; of &lt;em&gt;cardiovascular agents,&lt;/em&gt; including &lt;em&gt;tissue plasminogen activator,&lt;/em&gt; over the next two &lt;em&gt;years&lt;/em&gt;.</str>
        <int name="index">8</int>
      </lst>
      <lst name="sentence">
        <str name="text">&lt;em&gt;SmithKline Beckman&lt;/em&gt; Corp said it is pursuing a &lt;em&gt;three-point stragey&lt;/em&gt; that will &lt;em&gt;achieve&lt;/em&gt; a 10 pct &lt;em&gt;annual increase&lt;/em&gt; in &lt;em&gt;operating earnings&lt;/em&gt; throughout the &lt;em&gt;remainder&lt;/em&gt; of the &lt;em&gt;decade&lt;/em&gt;.</str>
        <int name="index">0</int>
      </lst>
      <lst name="sentence">
        <str name="text">To &lt;em&gt;bolster&lt;/em&gt; its &lt;em&gt;position&lt;/em&gt; in the &lt;em&gt;antiulcer market,&lt;/em&gt; in which &lt;em&gt;Tagamet&lt;/em&gt; has met &lt;em&gt;stiff competition, SmithKline&lt;/em&gt; said its &lt;em&gt;strategy&lt;/em&gt; to &lt;em&gt;develop&lt;/em&gt; an over-the-&lt;em&gt;counter version&lt;/em&gt; of &lt;em&gt;Tagamet&lt;/em&gt; is bolstered by two &lt;em&gt;joint ventures,&lt;/em&gt; one with &lt;Wellcome PLC&gt;, and one pending &lt;em&gt;venture&lt;/em&gt; in &lt;em&gt;Japan&lt;/em&gt;.</str>
        <int name="index">4</int>
      </lst>
    </lst>
  </lst>
</lst>
</response>
